Plus Therapeutics (PSTV) 10-Q 14 May 19 2019 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Mar. 31, 2019	Apr. 30, 2019
Document And Entity Information [Abstract]
Entity Registrant Name	CYTORI THERAPEUTICS, INC.
Entity Central Index Key	0001095981
Trading Symbol	CYTX
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Emerging Growth Company	false
Entity Small Business	true
Entity Common Stock, Shares Outstanding		22,155,795
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	Q1
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2019

CONSOLIDATED CONDENSED BALANCE

CONSOLIDATED CONDENSED BALANCE SHEETS (UNAUDITED) - USD ($) $ in Thousands	Mar. 31, 2019	Dec. 31, 2018
Current assets:
Cash and cash equivalents	$ 3,872	$ 5,261
Accounts receivable, net of reserves of $185 in 2019 and $185 in 2018	455	286
Restricted cash	40	40
Inventories, net	3,003	2,947
Other current assets	1,092	1,114
Total current assets	8,462	9,648
Property and equipment, net	2,607	2,559
Operating lease right-of-use assets	2,153
Other assets	1,827	1,905
Intangibles, net	5,645	5,957
Goodwill	3,922	3,922
Total assets	24,616	23,991
Current liabilities:
Accounts payable and accrued expenses	3,224	3,357
Operating lease liability	700
Term loan obligations, net of discount	14,371	14,202
Total current liabilities	18,295	17,559
Deferred revenues	142	167
Other noncurrent liabilities	98	124
Noncurrent operating lease liability	1,518
Warrant liability	706	916
Total liabilities	20,759	18,766
Commitments and contingencies (Notes 8 and 9)
Stockholders’ equity:
Preferred stock, $0.001 par value; 5,000,000 shares authorized; 30,233 shares issued; 4,540 and 4,606 shares outstanding in 2019 and 2018, respectively
Common stock, $0.001 par value; 100,000,000 shares authorized; 21,905,795 and 14,830,414 shares issued and outstanding in 2019 and 2018, respectively	22	15
Additional paid-in capital	420,290	418,375
Accumulated other comprehensive income	1,078	1,218
Accumulated deficit	(417,533)	(414,383)
Total stockholders’ equity	3,857	5,225
Total liabilities and stockholders’ equity	$ 24,616	$ 23,991

CONSOLIDATED CONDENSED BALANC_2

CONSOLIDATED CONDENSED BALANCE SHEETS (UNAUDITED) (Parenthetical) - USD ($) $ in Thousands	Mar. 31, 2019	Dec. 31, 2018
Current assets:
Accounts receivable, reserves	$ 185	$ 185
Stockholders’ equity:
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	5,000,000	5,000,000
Preferred stock, shares issued (in shares)	30,233	30,233
Preferred stock, shares outstanding (in shares)	4,540	4,606
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	100,000,000	100,000,000
Common stock, shares issued (in shares)	21,905,795	21,905,795
Common stock, shares outstanding (in shares)	14,830,414	14,830,414

CONSOLIDATED CONDENSED STATEMEN

CONSOLIDATED CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (UNAUDITED) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Income Statement [Abstract]
Product revenues	$ 703	$ 731
Cost of product revenues	(353)	(273)
Amortization of intangible assets	(306)	(306)
Gross profit	44	152
Development revenues:
Government contracts and other	737	917
Total development revenues	737	917
Operating expenses:
Research and development	1,846	2,499
Sales and marketing	428	678
General and administrative	1,508	2,244
Total operating expenses	3,782	5,421
Operating loss	(3,001)	(4,352)
Other income (expense):
Interest income	7	14
Interest expense	(515)	(423)
Other income (expense), net	149	352
Change in fair value of warrants	210	0
Total other expense	(149)	(57)
Net loss	$ (3,150)	$ (4,409)
Basic and diluted net loss per share attributable to common stockholders	$ (0.18)	$ (0.73)
Basic and diluted weighted average shares used in calculating net loss per share attributable to common stockholders	17,657,108	6,017,791
Comprehensive loss:
Net loss	$ (3,150)	$ (4,409)
Other comprehensive loss – foreign currency translation adjustments	(140)	(281)
Comprehensive loss	$ (3,290)	$ (4,690)

CONSOLIDATED CONDENSED STATEM_2

CONSOLIDATED CONDENSED STATEMENTS OF STOCKHOLDERS' EQUITY (UNAUDITED) - USD ($) $ in Thousands	Total	Convertible Preferred Stock [Member]	Convertible Preferred Stock [Member]Series B Convertible Preferred Stock [Member]	Convertible Preferred Stock [Member]Series C Convertible Preferred Stock [Member]	Common Stock [Member]	Common Stock [Member]Series B Convertible Preferred Stock [Member]	Common Stock [Member]Series C Convertible Preferred Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Other Comprehensive Income [Member]	Accumulated Deficit [Member]
Balance at Dec. 31, 2017	$ 13,000				$ 6			$ 413,356	$ 1,387	$ (401,749)
Balance (in shares) at Dec. 31, 2017		2,431			5,782,573
Share-based compensation	143							143
Sale of common stock, net	27							27
Sale of common stock, net (in shares)					10,069
Conversion of Convertible Preferred Stock into common stock (share)			(1,228)			368,738
Foreign currency translation adjustment and accumulated other comprehensive income	(281)								(281)
Net loss	(4,409)									(4,409)
Balance at Mar. 31, 2018	8,480				$ 6			413,526	1,106	(406,158)
Balance (in shares) at Mar. 31, 2018		1,203			6,161,380
Balance at Dec. 31, 2018	$ 5,225				$ 15			418,375	1,218	(414,383)
Balance (in shares) at Dec. 31, 2018	14,830,414	4,606			14,830,414
Share-based compensation	$ 49							49
Sale of common stock, net	1,873				$ 7			1,866
Sale of common stock, net (in shares)					6,992,736
Conversion of Convertible Preferred Stock into common stock (share)				(66)			82,645
Foreign currency translation adjustment and accumulated other comprehensive income	(140)								(140)
Net loss	(3,150)									(3,150)
Balance at Mar. 31, 2019	$ 3,857				$ 22			$ 420,290	$ 1,078	$ (417,533)
Balance (in shares) at Mar. 31, 2019	14,830,414	4,540			21,905,795

CONSOLIDATED CONDENSED STATEM_3

CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Cash flows from operating activities:
Net loss	$ (3,150)	$ (4,409)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	443	497
Amortization of deferred financing costs and debt discount	168	105
Provision for excess inventory	0	326
Change in fair value of warrants	(210)	0
Share-based compensation expense	49	143
Loss on asset disposal	0	22
Increases (decreases) in cash caused by changes in operating assets and liabilities:
Accounts receivable	(212)	(747)
Inventories	16	141
Other current assets	16	301
Other assets	1	(24)
Accounts payable and accrued expenses	(405)	(556)
Deferred revenues	(25)	84
Other long-term liabilities	39	(2)
Net cash used in operating activities	(3,270)	(4,119)
Cash flows from investing activities:
Purchases of property and equipment /long-lived assets	(6)	(53)
Net cash used in investing activities	(6)	(53)
Cash flows from financing activities:
Payment of financing lease liability	(28)	0
Proceeds from sale of common stock, net	1,919	(150)
Net cash provided by (used in) financing activities	1,891	(150)
Effect of exchange rate changes on cash and cash equivalents	(4)	39
Net decrease in cash and cash equivalents	(1,389)	(4,283)
Cash, cash equivalents, and restricted cash at beginning of period	5,301	10,225
Cash, cash equivalents, and restricted cash at end of period	3,912	5,942
Cash paid during period for:
Interest	347	311
Supplemental schedule of non-cash investing and financing activities:
Conversion of preferred stock into common stock	$ 0	$ 4

Basis of Presentation and New A

Basis of Presentation and New Accounting Standards	3 Months Ended
	Mar. 31, 2019
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Basis of Presentation and New Accounting Standards	1. Basis of Presentation and New Accounting Standards Our accompanying unaudited consolidated condensed financial statements as of March 31, 2019 and for the three months ended March 31, 2019 and 2018 have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America for annual financial statements. Our consolidated condensed balance sheet at December 31, 2018 has been derived from the audited financial statements at December 31, 2018, but does not include all of the information and footnotes required by accounting principles generally accepted in the United States of America for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation of the financial position and results of operations of Cytori Therapeutics, Inc., and our subsidiaries (collectively, the “Company”) have been included. Operating results for the three months ended March 31, 2019 are not necessarily indicative of the results that may be expected for the year ending December 31, 2018. These financial statements should be read in conjunction with the consolidated financial statements and notes therein included in our Annual Report on Form 10-K for the year ended December 31, 2018, filed with the Securities and Exchange Commission on March 29, 2019. Amendments to Certificate of Incorporation and Reverse Stock Split On May 23, 2018, following stockholder and Board approval, the Company filed a Certificate of Amendment to its Amended and Restated Certificate of Incorporation, as amended (the “Amendment”), with the Secretary of State of the State of Delaware to (i) effectuate a one-for-ten (1:10) reverse stock split (the “Reverse Stock Split”) of its common stock, par value $0.001 per share, without any change to its par value, and (ii) increase the number of authorized shares of the Company’s common stock from 75 million to 100 million shares (which amount is not otherwise affected by the Reverse Stock Split). The Amendment became effective on the filing date. Upon effectiveness of the Reverse Stock Split, the number of shares of the Company’s common stock (x) issued and outstanding decreased from approximately 61.6 million shares (as of May 23, 2018) to approximately 6.2 million shares; (y) reserved for issuance upon exercise of outstanding warrants and options decreased from approximately 23.4 million shares to approximately 2.3 million shares, and (z) reserved but unallocated under our current equity incentive plans (including the stockholder-approved share increase to the Company’s 2014 Equity Incentive Plan) decreased from approximately 9.1 million common shares to approximately 0.9 million common shares. The Company’s 5,000,000 shares of authorized Preferred Stock were not affected by the Reverse Stock Split. No fractional shares were issued in connection with the Reverse Stock Split. Proportional adjustments for the reverse stock split were made to the Company's outstanding stock options, warrants and equity incentive plans for all periods presented. Recently Issued and Recently Adopted Accounting Pronouncements Recently Issued Accounting Pronouncements In February 2017, the FASB issued ASU 2017-04, Simplifying the Test for Goodwill Impairment Recently Adopted Accounting Pronouncements In February 2016, the Financial Accounting Standards Board (the “FASB”) issued Accounting Standards Update (“ASU”) 2016-02, Leases .

Use of Estimates

Use of Estimates	3 Months Ended
	Mar. 31, 2019
Use Of Estimates [Abstract]
Use of Estimates	2. Use of Estimates The preparation of consolidated financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions affecting the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenue and expenses during the reporting period. Our most significant estimates and critical accounting policies involve recognizing revenue, reviewing goodwill and intangible assets for impairment, determining the assumptions used in measuring share-based compensation expense, valuing warrants, measuring expense related to our in-process research and development Actual results could differ from these estimates. Management’s estimates and assumptions are reviewed regularly, and the effects of revisions are reflected in the consolidated financial statements in the periods they are determined to be necessary.

Liquidity

Liquidity	3 Months Ended
	Mar. 31, 2019
Liquidity [Abstract]
Liquidity	3. Liquidity We incurred net losses of $3.2 million for the three months ended March 31, 2019. We have an accumulated deficit of $417.5 million as of March 31, 2019. Additionally, we used net cash of $3.3 million to fund our operating activities for the three months ended March 31, 2019. Further, the Loan and Security Agreement (defined in Note 4), with Oxford Finance, LCC (“Oxford”), as further described in Note 4, requires maintenance of a minimum of $2.0 million in unrestricted cash and cash equivalents on hand to avoid an event of default under the Loan and Security Agreement. Based on our cash and cash equivalents on hand of approximately $3.9 million at March 31, 2019, the Company estimates that it will need to raise additional capital and/or obtain a waiver or restructure the Loan and Security Agreement in the near term to avoid defaulting under its $2.0 million minimum cash/cash equivalents covenant. To date, these operating losses have been funded primarily from outside sources of invested capital including our recently completed 2018 Rights Offering (defined in Note 3 below), our Lincoln Park Purchase Agreement (defined in Note 11) with Lincoln Park Capital Fund, LLC (“Lincoln Park”), the Loan and Security Agreement and gross profits. We have had, and we will continue to have, an ongoing need to raise additional cash from outside sources to fund our future clinical development programs and other operations. Our inability to raise additional cash would have a material and adverse impact on operations and would cause us to default on our loan. On June 1, 2018, we entered into a Sales Agreement with B. Riley FBR, Inc. (“B. Riley FBR”) to sell shares of our common stock an aggregate offering price of up to $6.5 million from time to time, through an “at the market” equity offering program (the “ATM program”) under which B. Riley FBR will act as sales agent. On July 25, 2018, we closed a rights offering originally filed under a Form S-1 registration statement in April 2018 (“2018 Rights Offering”). Pursuant to the 2018 Rights Offering, the Company sold an aggregate of 6,723 units consisting of a total of 6,723 shares of Series C Convertible Preferred Stock, immediately convertible into approximately 8.4 million shares of common stock and 7,059,150 warrants, with each warrant exercisable for one share of common stock at an exercise price of $0.7986 per share, resulting in total net proceeds to the Company of approximately $5.7 million. On August 28, 2018, we received a written notice from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, based upon the closing bid price of our common stock for the prior 30 consecutive business days, we no longer meet the requirement to maintain a minimum bid price of $1.00 per share, as set forth in Nasdaq Listing Rule 5550(a)(2). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), we were provided an initial period of 180 calendar days, or until February 25, 2019, in which to regain compliance. We were granted an additional compliance period of 180 calendar days, or until August 26, 2019, in which to regain compliance after meeting the continued listing requirement for market value of publicly held shares and all other initial listing standards for the Nasdaq Capital Market, with the exception of the bid price requirement, and providing notice to Nasdaq staff of our intent to cure the deficiency during this second compliance period, by effecting a reverse stock split, if necessary. In order to regain compliance with the minimum bid price requirement, the closing bid price of our common stock must have been at least $1.00 per share for a minimum of ten consecutive business days during the 180-day period. On September 21, 2018, Cytori entered into a purchase agreement and a registration rights agreement, with Lincoln Park, pursuant to which the Company has the right to sell to Lincoln Park and Lincoln Park is obligated to purchase up to $5.0 million of shares of the Company’s common stock over the 24-month period following October 15, 2018, subject to the satisfaction of certain conditions. Through December 31, 2018, the Company sold a total of 0.6 million shares for proceeds of approximately $0.3 million through the Lincoln Park Purchase Agreement and no shares were sold during the three months ended March 31, 2019. See Note 11 for further discussion on the Lincoln Park Agreement. We continue to seek additional capital through product revenues, strategic transactions, including extension opportunities under our awarded U.S. Department of Health and Human Service’s Biomedical Advanced Research and Development Authority (“BARDA”) contract, and from other financing alternatives. Without additional capital, current working capital and cash generated from sales will not provide adequate funding for research, sales and marketing efforts and product development activities at their current levels. If sufficient capital is not raised, we will at a minimum need to significantly reduce or curtail our research and development and other operations, and this would negatively affect our ability to achieve corporate growth goals. On April 24, 2019 the Company received $3.4 million of net cash proceeds related to the sale of the Company’s UK subsidiary, Cytori Ltd., and the Company’s Cell Therapy assets (excluding such assets used in Japan or relating to the Company’s contract with BARDA), of which $1.7 million was used to pay down principal, interest and fees on the Loan and Security Agreement, and on April 25, 2019 the Company received $2.5 million of net cash proceeds related to the sale of the Cytori Therapeutics, K.K., and substantially all of the Company’s Cell Therapy assets used in Japan, of which $1.4 million was used to pay down principal, interests and fees on the Loan and Security Agreement (See Note 12). Should we be unable to raise additional cash from outside sources, this would have a material adverse impact on our operations. The accompanying consolidated condensed financial statements have been prepared assuming the Company will continue to operate as a going concern, which contemplates the realization of assets and settlement of liabilities in the normal course of business, and do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from uncertainty related to its ability to continue as a going concern.

Term Loan Obligations

Term Loan Obligations	3 Months Ended
	Mar. 31, 2019
Debt Disclosure [Abstract]
Term Loan Obligations	4. Term Loan Obligations On May 29, 2015, the Company On September 20, 2017, the Company entered into an amendment to the Term Loan, pursuant to which, among other things, Oxford agreed to reduce the minimum liquidity covenant level originally at $5 million to $1.5 million. The amendment also extended the interest-only period under the Loan and Security Agreement through August On June 19, 2018, the Company entered into a second amendment (the “Second Amendment”) to the Term Loan with Oxford. The Second Amendment extends the interest-only period under the Term Loan to December 1, 2018 if the Company receives unrestricted gross cash proceeds of at least $15 million from the sale and issuance of the Company’s equity securities on or before August 31, 2018. The Company agreed to pay Oxford an amendment fee of $250,000 at the earlier of maturity or acceleration of the loan. On August 31, 2018, the Company entered into a third amendment (the “Third Amendment”) to the Term Loan with Oxford. The Third Amendment extends the interest-only period under the Term Loan to December 31, 2018 and also requires that the Company pay to Oxford, in accordance with its pro rata share of the loans, 75% of all proceeds received (i) from the issuance and sale of unsecured subordinated convertible debt, (ii) in connection with a joint venture, collaboration or other partnering transaction, (iii) in connection with any licenses, (iv) from dividends (other than non-cash dividends from wholly owned subsidiaries) and (v) from the sale of any assets (such requirement, the “Prepayment Requirement”). The Prepayment Requirement does not apply to proceeds from the sale and issuance of the Company’s equity securities, other than convertible debt. The Prepayment Requirement shall apply until an aggregate principle amount of $7.0 million has been paid pursuant to the Prepayment Requirement. However, if less than $7.0 million has been paid pursuant to the Prepayment Requirement on December 31, 2018 then the Company is required to promptly make additional payments until an aggregate principal amount of $7.0 million has been paid. The Company agreed to pay Oxford an amendment fee of $50,000 at the earlier of maturity or acceleration of the loan. On December 31, 2018, the Company entered into a fourth amendment (the “Fourth Amendment”) to the Term Loan with Oxford. Oxford agreed to extend the maturity date from June 1, 2019 to June 1, 2020. The Amendment increased the minimum liquidity covenant level from $1.5 million to $2.0 million and extended the interest-only period under the Loan and Security Agreement to March 1, 2019. The Amendment also required that the Company achieve one of the following by January 31, 2019: enter into an asset sale agreement with a minimum unrestricted net cash proceeds to the Company of $4.0 million; enter into a binding agreement for the issuance and sale of its equity securities or unsecured convertible subordinated debt which would result in unrestricted gross cash proceeds of not less than $7.5 million; or enter into a merger agreement pursuant to which the obligations under the Loan and Security Agreement would be paid down to a level satisfactory to Oxford. On February 13, 2019, the Company entered into a fifth amendment (the “Fifth Amendment”) to the Term Loan primarily to extend the January 31, 2019 obligations under the Fourth Amendment to February 28, 2019. On March 4, 2019, the Company entered into a sixth amendment to the Term Loan primarily to extend the Fifth Amendment obligations to March 29, 2019. On April 29, 2019, the Company entered into a seventh amendment (the “Seventh Amendment”) to the Term Loan, pursuant to which, among other things, Oxford agreed to interest only payments starting May 1, 2019, with amortization payments resuming on May 1, 2020. See Note 12 for further discussion on the The Term Loan, as amended, is collateralized by a security interest in substantially all of the Company’s existing and subsequently acquired assets, including its intellectual property assets, subject to certain exceptions set forth in the Loan and Security Agreement, as amended. The intellectual property asset collateral will be released upon the Company achieving certain liquidity level when the total principal outstanding under the Loan and Security Agreement is less than $3 million. Our interest expense for the three months ended March 31, 2019 and 2018 and , The Loan and Security Agreement, as amended, contains customary indemnification obligations and customary events of default, including, among other things, our failure to fulfill certain obligations under the Term Loan, as amended, and the occurrence of a material adverse change, which is defined as a material adverse change in our business, operations, or condition (financial or otherwise), a material impairment of the prospect of repayment of any portion of the loan. In the event of default by us or a declaration of material adverse change by our lender, under the Term Loan, the lender would be entitled to exercise its remedies thereunder, including the right to accelerate the debt, upon which we may be required to repay all amounts then outstanding under the Term Loan, which could materially harm our financial condition. As of March 31, 2019, we were in compliance with all covenants under the Term Loan and have not received any notification or indication from Oxford to invoke the material adverse change clause. However, due to our current cash flow position and the substantial doubt about our ability to continue as a going concern, the entire principal amount of the Term Loan is presented as short-term. We will continue to evaluate the debt classification on a quarterly basis and evaluate for reclassification in the future should our financial condition improve.

Revenue Recognition

Revenue Recognition	3 Months Ended
	Mar. 31, 2019
Revenue Recognition [Abstract]
Revenue Recognition	5. Revenue Recognition Product Sales Our revenue is generated primarily from the sale of products. Product revenue primarily consists of sales of Celution devices and consumables for commercial and research purposes. The Company’s contracts with customers only include one performance obligation (i.e., sale of the Company’s products). Typically, if there are multiple items included on a single order, they are delivered at the same time. Revenue is recognized at a point in time when delivery is completed and control of the promised goods is transferred to the customers. Revenue is measured as the amount of consideration the Company expects to be entitled to in exchange for those goods. The Company’s contracts do not involve financing elements as payment terms with customers are less than one year. The sale arrangements do not include any variable consideration. Advance payments from customers are recorded as deferred revenue. Shipping and handling activities that occur after the customer obtains control of the goods are considered part of the Company’s obligation to transfer the products and therefore are recorded as direct selling expenses, as incurred. The following table represents revenue by product (in thousands): Three months ended March 31, 2019 March 31, 2018 Consumable $ 663 $ 559 Device - 94 Other products 40 78 $ 703 $ 731 Product revenues, classified by geographic location, are as follows (in thousands): Three months ended March 31, 2019 March 31, 2018 Product Revenues % of Total Product Revenues % of Total Americas $ 64 9 % $ 45 6 % Japan 419 60 % 578 79 % EMEA 150 21 % 90 12 % Asia Pacific 70 10 % 18 3 % Total product revenues $ 703 100 % $ 731 100 % Concentration of Significant Customers Two direct customers accounted for 57% of our revenue recognized for the three months ended March 31, 2019 March 31, 2019 Four direct customers comprised 66% of our revenue recognized for the three months ended March 31, 2018 March 31, 2018 Development Revenue We earn revenue for performing tasks under research and development agreements with governmental agencies like BARDA which is outside of the scope of the new revenue recognition guidance. Revenues derived from reimbursement of direct out-of-pocket expenses for research costs associated with government contracts are recorded as government contracts and other within development revenues. Government contract revenue is recorded at the gross amount of the reimbursement. The costs associated with these reimbursements are reflected as a component of research and development expense in our statements of operations. We recognized $0.7 million in development revenue for the three months ended

Inventories

Inventories	3 Months Ended
	Mar. 31, 2019
Inventory Disclosure [Abstract]
Inventories	6. Inventories Inventories are carried at the lower of cost or net realizable value, determined on the first-in, first-out (FIFO) method. Inventories consisted of the following (in thousands): March 31, 2019 December 31, 2018 Raw materials $ 663 $ 758 Work in process 662 555 Finished goods 1,678 1,634 $ 3,003 $ 2,947

Loss per Share

Loss per Share	3 Months Ended
	Mar. 31, 2019
Earnings Per Share [Abstract]
Loss per Share	7. Loss per Share Basic per share data is computed by dividing net income or loss applicable to common stockholders by the weighted average number of common shares outstanding during the period. Diluted per share data is computed by dividing net income or loss applicable to common stockholders by the weighted average number of common shares outstanding during the period increased to include, if dilutive, the number of additional common shares that would have been outstanding as calculated using the treasury stock method. Potential common shares were related to outstanding but unexercised options, multiple series of preferred stock, and warrants for all periods presented. We have excluded all potentially dilutive securities from the calculation of diluted loss per share attributable to common stockholders as of March 31, 2019 and 2018, as their inclusion would be antidilutive. Potentially dilutive common shares excluded from the calculations of diluted loss per share were 13.6 million as of March 31, 2019, which includes 8.9 million outstanding warrants and 0.1 million options, 4.6 million shares of preferred stock, and restricted stock awards. Potentially dilutive common shares excluded from the calculation of diluted loss per share were 2.3 million as of .

Commitments

Commitments	3 Months Ended
	Mar. 31, 2019
Commitments [Abstract]
Commitments	8. Commitments Leases At the inception of a contractual arrangement, the Company determines whether the contract contains a lease by assessing whether there is an identified asset and whether the contract conveys the right to control the use of the identified asset in exchange for consideration over a period of time. If both criteria are met, the Company calculates the associated lease liability and corresponding right-of-use asset upon lease commencement using a discount rate based on the rate implicit in the lease or an incremental borrowing rate commensurate with the term of the lease. The Company records lease liabilities within current liabilities or long-term liabilities based upon the length of time associated with the lease payments. The Company records its operating lease right-of-use assets as long-term assets. Right-of-use assets for financing leases are recorded within property and equipment, net in the Balance Sheet. Leases with an initial term of 12 months or less are not recorded on the Balance Sheet. Instead, the Company recognizes lease expense for these leases on a straight-line basis over the lease term. In connection with certain operating leases, the Company has security deposits recorded and maintained as restricted cash totaling $0.4 million as of March 31, 2019. The Company leases office and storage facilities and equipment under various operating and financing lease agreements. The initial terms of these leases range from 2 to 11 years and generally provide for periodic rent increases, and renewal and termination options. The Company’s lease agreements do not contain any material variable lease payments, residual value guarantees or material restrictive covenants. Certain leases require the Company to pay taxes, insurance, and maintenance. Payments for the transfer of goods or services such as common area maintenance and utilities represent non-lease components. The Company elected the package of practical expedients and therefore does not separate non-lease components from lease components. The table below summarizes the Company’s lease liabilities and corresponding right-of-use assets (in thousands) March 31, 2019 Assets Operating $ 2,153 Financing 215 Total leased assets $ 2,368 Liabilities Current: Operating $ 700 Financing 130 Noncurrent: Operating $ 1,518 Financing 84 Total lease liabilities $ 2,432 The table below summarizes the Company’s lease costs from its Unaudited Consolidated Statement of Operations, and cash payments from its Unaudited Consolidated Statement of Cash Flows during the three months ended March 31, 2019 (in thousands, except years and rates): March 31, 2019 Lease expense: Operating lease expense $ 176 Finance lease expense: Depreciation of right-of-use assets 33 Interest expense on lease liabilities - Total lease expense $ 209 Cash payment information: Operating cash used for operating leases $ 176 Financing cash used for financing leases 28 Total cash paid for amounts included in the measurement of lease liabilities $ 204 Weighted-average remaining lease term (years) - operating leases 4.9 Weighted-average remaining lease term (years) - finance leases 1.8 Weighted-average discount rate - operating leases 7.3 % Weighted-average discount rate - finance leases 5.0 % The Company’s future minimum annual lease payments under operating and financing leases at March 31, 2019 are as follows in (thousands): Financing Operating Leases Leases Remaining 2019 $ 100 $ 527 2020 120 690 2021 7 668 2022 - 281 2023 - 100 Thereafter - 447 Total minimum lease payments $ 227 $ 2,713 Less: amount representing interest (13 ) (495 ) Present value of obligations under leases 214 2,218 Less: current portion (130 ) (700 ) Noncurrent lease obligations $ 84 $ 1,518 Other commitments We have entered into agreements with various research organizations for pre-clinical and clinical development studies, which have provisions for cancellation. Under the terms of these agreements, the vendors provide a variety of services including conducting research, recruiting and enrolling patients, monitoring studies and data analysis. Payments under these agreements typically include fees for services and reimbursement of expenses. The timing of payments due under these agreements is estimated based on current study progress. As of March 31, 2019 which We were party to an agreement with Roche Diagnostics Corporation (“Roche”) On June 8, 2018, the Company received written notice from Roche terminating its existing supply agreement with the Company due to failure by the Company to meet minimum purchase requirements. Roche has indicated to the Company that it will agree to negotiate in good faith with the Company with respect to a new supply agreement for enzymes with specifications similar to the enzymes that Roche was previously manufacturing for the Company.

Contingencies

Contingencies	3 Months Ended
	Mar. 31, 2019
Commitments And Contingencies Disclosure [Abstract]
Contingencies	9. Contingencies We are subject to various claims and contingencies related to legal proceedings. Due to their nature, such legal proceedings involve inherent uncertainties including, but not limited to, court rulings, negotiations between affected parties and governmental actions. Management assesses the probability of loss for such contingencies and accrues a liability and/or discloses the relevant circumstances, as appropriate. Management believes that any liability to us that may arise as a result of currently pending legal proceedings will not have a material adverse effect on our financial condition, liquidity, or results of operations as a whole. On August 31, 2018, we filed a Demand for Arbitration with the American Arbitration Association in San Diego, California, against Bimini Technologies LLC (“Bimini”) for fraud and breach of a Sale and Exclusive License/Supply Agreement made in 2013 under which Bimini licensed rights to the Company’s Standalone Fat Transplantation, including the Puregraft Product Line and associated trademarks. Our arbitration demand alleges that Bimini failed to make a $1.0 million milestone payment due to the Company after Bimini achieved $10.0 million in gross profits from the sale of the Company’s Puregraft product line, and Bimini deceived the Company about Bimini’s true gross profits figures. Our arbitration demand seeks that $1.0 million milestone payment, as well prejudgment interest and attorneys’ fees. On October 29, 2018 Bimini made the $1.0 million milestone payment. The parties subsequently entered into a settlement agreement resolving the claims in the Demand for Arbitration.

Financial Instruments

Financial Instruments	3 Months Ended
	Mar. 31, 2019
Investments All Other Investments [Abstract]
Financial Instruments	10. Financial Instruments We disclose fair value information about all financial instruments, whether or not recognized in the balance sheet, for which it is practicable to estimate fair value. The disclosures of estimated fair value of financial instruments at March 31, 2019 , The carrying amounts for cash and cash equivalents, accounts receivable, other current assets, accounts payable, accrued expenses and other liabilities approximate fair value due to the short-term nature of these instruments. Further, based on the borrowing rates currently available for loans with similar terms, we believe the fair value of long-term debt approximates its carrying value. Fair value measurements are market-based measurements, not entity-specific measurements. Therefore, fair value measurements are determined based on the assumptions that market participants would use in pricing the asset or liability. We follow a three-level hierarchy to prioritize the inputs used in the valuation techniques to derive fair values. The basis for fair value measurements for each level within the hierarchy is described below: • Level 1: Quoted prices in active markets for identical assets or liabilities. • Level 2: Quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations in which all significant inputs are observable in active markets. • Level 3: Valuations derived from valuation techniques in which one or more significant inputs are unobservable in active markets. The changes in the fair value of liability classified warrants are included in net income (loss) for the respective periods. Because some of the inputs to our valuation model are either not observable or are not derived principally from or corroborated by observable market data by correlation or other means, the warrant liability is classified as Level 3 in the fair value hierarchy.

Stockholders' Equity

Stockholders' Equity	3 Months Ended
	Mar. 31, 2019
Stockholders Equity Note [Abstract]
Stockholders' Equity	11. Preferred Stock The Company has authorized 5,000,000 shares of preferred stock, par value $0.001 per share. The Company’s Board of Directors is authorized to designate the terms and conditions of any preferred stock we issue without further action by the common stockholders. There were 13,500 shares of Series A 3.6% Convertible Preferred Stock, 10,000 Series B Preferred Stock and On July 25, 2018, the Company filed a Certificate of Designation of Preferences, Rights and Limitations of Series C Convertible Preferred Stock (the “Certificate of Designation”) with the Delaware Secretary of State creating a new series of its authorized preferred stock, par value $0.001 per share, designated as the Series C Convertible Preferred Stock (the “Series C Preferred Stock”). The number of shares initially constituting the Series C Preferred Stock was set at 7,000 shares. Pursuant to a registration statement on Form S-1 originally filed on April 27, 2018, as amended, and became effective on July 17, 2018, and related prospectus (as supplemented), the Company registered and distributed to holders of its common stock and Series B Convertible Preferred Stock, at no charge, non-transferable subscription rights to purchase up to an aggregate of 20,000 units each consisting of one share of Series C Preferred Stock and 1,050 warrants for $1,000 per unit. Each warrant is exercisable for one share of the Company’s common stock at an exercise price of $0.7986 per share for 30 months from the date of issuance and each share of Series C Preferred Stock is convertible into 1,253 shares of the Company's common stock. Pursuant to the 2018 Rights Offering, which closed on July 25, 2018, the Company sold an aggregate of 6,723 units, resulting in total net proceeds to the Company of approximately $5.7 million. The fair value of the common stock into which the Series C Preferred Stock was convertible on the date of issuance exceeded the proceeds allocated to the preferred stock, resulting in the beneficial conversion feature that we recognized as a deemed dividend to the preferred stockholders and, accordingly, an adjustment to net loss to arrive at net loss allocable to common stockholders. We recorded a deemed dividend within additional paid-in capital of $2.5 million for the quarter ended December 31, 2018, related to a beneficial conversion feature included in the issuance of our Series C Convertible Preferred Stock. Based on the relevant authoritative accounting guidance, the warrants were liability classified at the issuance date. The warrants may be redeemed by the Company at $0.01 per warrant prior to their expiration if the Company’s common stock closes above $3.63 per share , subject to adjustment, The initial fair value of the liability associated with these warrants was $3.1 million, and the fair value decreased to $1.5 million as of . The main driver for the change in the fair value of warrants at September 30, 2018, was related to the change in our stock price. All future changes in the fair value of the warrants will be recognized in our consolidated statements of operations until they are either exercised or expire. The warrants are not traded in an active securities market, and as such the estimated the fair value as of was determined by using an option pricing model with the following assumptions: As of As of December31, 2018 Expected term 1.8 years 2.1 years Common stock market price $ 0.26 $ 0.29 Risk-free interest rate 2.38% 2.48% Expected volatility 128% 125% Resulting fair value (per warrant) $ 0.10 $ 0.13 Expected volatility was computed using daily pricing observations of traded shares of Cytori for recent periods that correspond to the expected term of the warrants. We believe this method produces an estimate that is representative of our expectations of future volatility over the expected term of these warrants. We currently have no reason to believe future volatility over the expected remaining life of these warrants is likely to differ materially from historical volatility. The expected life is based on the remaining contractual term of the warrants. The risk-free interest rate is the U.S. Treasury bond rate as of the valuation date. The following table summarizes the change in our Level 3 warrant liability value (in thousands): Warrant liability March 31, 2019 December 31, 2018 Beginning balance $ 916 $ 3,148 Change in fair value (210 ) (2,233 ) Ending balance $ 706 $ 916 Common Stock On June 1, 2018, the Company entered into a Sales Agreement with B. Riley FBR to sell shares of its common stock having an aggregate offering price of up to $6.5 million through its ATM program. Through March 31, 2019, the Company sold a total of 11.0 million shares for proceeds of approximately $3.8 million through the ATM program. On September 21, 2018

Subsequent Events

Subsequent Events	3 Months Ended
	Mar. 31, 2019
Subsequent Events [Abstract]
Subsequent Events	12. Sale of the UK Subsidiary and Certain Assets On March 30, 2019, the Company entered into an Asset and Share Sale and Purchase Agreement (the “Lorem Purchase Agreement”) with Lorem Vascular Pte. Ltd. (“Lorem”), pursuant to which, among other things, Lorem agreed to purchase the Company’s UK subsidiary, Cytori Ltd. (the “UK Subsidiary”), and the Company’s Cell Therapy assets, excluding such assets used in Japan or relating to the Company’s contract with BARDA The transaction was completed on April 24, 2019 and the Company received $4.0 million of cash proceeds, of which was used to pay down principal, interest and fees under the Loan and Security Agreement Sale of the Japanese Subsidiary and Certain Assets On April 19, 2019, the Company entered into an Asset and Share Sale and Purchase Agreement (the “Shirahama Purchase Agreement”) with Seijirō Shirahama, pursuant to which, among other things, Mr. Shirahama agreed to purchase the Company’s Japanese subsidiary, Cytori Therapeutics, K.K. (the “Japanese Subsidiary”), and substantially all of the Company’s Cell Therapy assets used in Japan. Both the Company and Mr. Shirahama have made customary representations, warranties and covenants in the Shirahama Purchase Agreement, which is subject to termination by either the Company or Mr. Shirahama upon the occurrence of specified events. The transaction was completed on April 25, 2019 and the Company received $3.0 million of cash proceeds, of which was used to pay down principal, interest and fees under the Loan and Security Agreement Accounting Assessment on the Sale of Assets The sale of the UK and Japanese Subsidiaries and related assets did not meet the criteria to be classified as held-for-sale as of March 31, 2019 as management did not have the authorization to commit to the sale until approval was obtained from the Board of Directors and Oxford in April 2019. The Company expects to recognize a loss on the disposal during the second quarter of 2019 however the amount has not yet been determined. The Company also performed a probability weighted undiscounted impairment assessment as of March 31, 2019 resulting in the conclusion that no impairment of the net assets included in the disposal group was required to be recognized as of March 31, 2019. Amendment to the Loan and Security Agreement On April 29, 2019, the Company entered into a seventh amendment, effective as of April 24, 2019 (the “Seventh Amendment”), to its existing Loan and Security Agreement with Oxford, pursuant to which, among other things, Oxford agreed to interest only payments starting May 1, 2019, with amortization payments resuming on May 1, 2020. The Seventh Amendment also requires that $1.7 million of the net proceeds received by the Company pursuant to the Lorem Purchase Agreement and $1.4 million of the net proceeds received by the Company pursuant to the Shirahama Purchase Agreement must be applied to prepay the loan. Additionally, the Seventh Amendment requires that the Company pay an amendment fee of $0.6 million at the earlier of the prepayment, maturity or acceleration of the loan.

Basis of Presentation and New_2

Basis of Presentation and New Accounting Standards (Policies)	3 Months Ended
	Mar. 31, 2019
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Basis of Presentation and New Accounting Standards	Our accompanying unaudited consolidated condensed financial statements as of March 31, 2019 and for the three months ended March 31, 2019 and 2018 have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America for annual financial statements. Our consolidated condensed balance sheet at December 31, 2018 has been derived from the audited financial statements at December 31, 2018, but does not include all of the information and footnotes required by accounting principles generally accepted in the United States of America for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation of the financial position and results of operations of Cytori Therapeutics, Inc., and our subsidiaries (collectively, the “Company”) have been included. Operating results for the three months ended March 31, 2019 are not necessarily indicative of the results that may be expected for the year ending December 31, 2018. These financial statements should be read in conjunction with the consolidated financial statements and notes therein included in our Annual Report on Form 10-K for the year ended December 31, 2018, filed with the Securities and Exchange Commission on March 29, 2019.
Recently Issued and Recently Adopted Accounting Pronouncements	Recently Issued and Recently Adopted Accounting Pronouncements Recently Issued Accounting Pronouncements In February 2017, the FASB issued ASU 2017-04, Simplifying the Test for Goodwill Impairment Recently Adopted Accounting Pronouncements In February 2016, the Financial Accounting Standards Board (the “FASB”) issued Accounting Standards Update (“ASU”) 2016-02, Leases .
Use of Estimates	The preparation of consolidated financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions affecting the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenue and expenses during the reporting period. Our most significant estimates and critical accounting policies involve recognizing revenue, reviewing goodwill and intangible assets for impairment, determining the assumptions used in measuring share-based compensation expense, valuing warrants, measuring expense related to our in-process research and development Actual results could differ from these estimates. Management’s estimates and assumptions are reviewed regularly, and the effects of revisions are reflected in the consolidated financial statements in the periods they are determined to be necessary.
Revenue Recognition	The Company’s contracts with customers only include one performance obligation (i.e., sale of the Company’s products). Typically, if there are multiple items included on a single order, they are delivered at the same time. Revenue is recognized at a point in time when delivery is completed and control of the promised goods is transferred to the customers. Revenue is measured as the amount of consideration the Company expects to be entitled to in exchange for those goods. The Company’s contracts do not involve financing elements as payment terms with customers are less than one year. The sale arrangements do not include any variable consideration. Advance payments from customers are recorded as deferred revenue. Shipping and handling activities that occur after the customer obtains control of the goods are considered part of the Company’s obligation to transfer the products and therefore are recorded as direct selling expenses, as incurred.

Revenue Recognition (Tables)

Revenue Recognition (Tables)	3 Months Ended
	Mar. 31, 2019
Revenue Recognition [Abstract]
Revenue by Product	The following table represents revenue by product (in thousands): Three months ended March 31, 2019 March 31, 2018 Consumable $ 663 $ 559 Device - 94 Other products 40 78 $ 703 $ 731
Product Revenues, Classified by Geographic Location	Product revenues, classified by geographic location, are as follows (in thousands): Three months ended March 31, 2019 March 31, 2018 Product Revenues % of Total Product Revenues % of Total Americas $ 64 9 % $ 45 6 % Japan 419 60 % 578 79 % EMEA 150 21 % 90 12 % Asia Pacific 70 10 % 18 3 % Total product revenues $ 703 100 % $ 731 100 %

Inventories (Tables)

Inventories (Tables)	3 Months Ended
	Mar. 31, 2019
Inventory Disclosure [Abstract]
Inventory	Inventories consisted of the following (in thousands): March 31, 2019 December 31, 2018 Raw materials $ 663 $ 758 Work in process 662 555 Finished goods 1,678 1,634 $ 3,003 $ 2,947

Commitments (Tables)

Commitments (Tables)	3 Months Ended
	Mar. 31, 2019
Commitments [Abstract]
Summary of Lease Liabilities and Right-of-Use Assets	The table below summarizes the Company’s lease liabilities and corresponding right-of-use assets (in thousands) March 31, 2019 Assets Operating $ 2,153 Financing 215 Total leased assets $ 2,368 Liabilities Current: Operating $ 700 Financing 130 Noncurrent: Operating $ 1,518 Financing 84 Total lease liabilities $ 2,432
Summary of Lease Costs	The table below summarizes the Company’s lease costs from its Unaudited Consolidated Statement of Operations, and cash payments from its Unaudited Consolidated Statement of Cash Flows during the three months ended March 31, 2019 (in thousands, except years and rates): March 31, 2019 Lease expense: Operating lease expense $ 176 Finance lease expense: Depreciation of right-of-use assets 33 Interest expense on lease liabilities - Total lease expense $ 209 Cash payment information: Operating cash used for operating leases $ 176 Financing cash used for financing leases 28 Total cash paid for amounts included in the measurement of lease liabilities $ 204 Weighted-average remaining lease term (years) - operating leases 4.9 Weighted-average remaining lease term (years) - finance leases 1.8 Weighted-average discount rate - operating leases 7.3 % Weighted-average discount rate - finance leases 5.0 %
Summary of Future Minimum Annual Lease Payments under Operating and Financing Leases	The Company’s future minimum annual lease payments under operating and financing leases at March 31, 2019 are as follows in (thousands): Financing Operating Leases Leases Remaining 2019 $ 100 $ 527 2020 120 690 2021 7 668 2022 - 281 2023 - 100 Thereafter - 447 Total minimum lease payments $ 227 $ 2,713 Less: amount representing interest (13 ) (495 ) Present value of obligations under leases 214 2,218 Less: current portion (130 ) (700 ) Noncurrent lease obligations $ 84 $ 1,518

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	3 Months Ended
	Mar. 31, 2019
Stockholders Equity Note [Abstract]
Schedule of Estimated Fair Value Determined Using Option Pricing Model Assumptions	The warrants are not traded in an active securities market, and as such the estimated the fair value as of As of As of December31, 2018 Expected term 1.8 years 2.1 years Common stock market price $ 0.26 $ 0.29 Risk-free interest rate 2.38% 2.48% Expected volatility 128% 125% Resulting fair value (per warrant) $ 0.10 $ 0.13
Summary of Change in Level 3 Warrant Liability Value	The following table summarizes the change in our Level 3 warrant liability value (in thousands): Warrant liability March 31, 2019 December 31, 2018 Beginning balance $ 916 $ 3,148 Change in fair value (210 ) (2,233 ) Ending balance $ 706 $ 916

Basis of Presentation and New_3

Basis of Presentation and New Accounting Standards (Details) $ / shares in Units, $ in Thousands	May 23, 2018$ / sharesshares	Mar. 31, 2019USD ($)$ / sharesshares	Dec. 31, 2018$ / sharesshares	May 24, 2018shares
Basis Of Presentation And New Accounting Standards [Line Items]
Reverse stock split of common stock	0.1
Common stock, par value (in dollars per share) | $ / shares	$ 0.001	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	75,000,000	100,000,000	100,000,000	100,000,000
Common stock, shares issued (in shares)	61,600,000	21,905,795	21,905,795	6,200,000
Common stock, shares outstanding (in shares)	61,600,000	14,830,414	14,830,414	6,200,000
Number of shares callable by warrants (in shares)	23,400,000			2,300,000
Preferred stock, shares authorized (in shares)	5,000,000	5,000,000	5,000,000	5,000,000
Common stock, reverse stock split, fractional shares issued	0
Operating lease right-of-use assets | $		$ 2,153
Operating lease, liability | $		$ 2,218
2014 Equity Incentive Plan [Member]
Basis Of Presentation And New Accounting Standards [Line Items]
Number of shares callable by warrants (in shares)	9,100,000			900,000

Liquidity (Details)

Liquidity (Details) - USD ($)

Apr. 25, 2019

Apr. 24, 2019

Sep. 21, 2018

Aug. 28, 2018

Jul. 25, 2018

Jun. 01, 2018

Mar. 31, 2019

Mar. 31, 2018

Dec. 31, 2018

Mar. 31, 2019

May 24, 2018

May 23, 2018

Liquidity [Line Items]

Net loss

$ 3,150,000

$ 4,409,000

Accumulated deficit

(417,533,000)

$ (414,383,000)

$ (417,533,000)

Net cash used in operating activities

$ (3,270,000)

(4,119,000)

Substantial doubt about going concern, description

These factors raise substantial doubt about the Company’s ability to continue as a going concern.

Cash and cash equivalents

$ 3,872,000

5,261,000

3,872,000

Minimum cash/cash equivalents covenant

2,000,000

2,000,000

Proceeds from sale of common stock, net

1,919,000

(150,000)

Common stock issued (in shares)

6,723

Number of shares callable by warrants (in shares)

2,300,000

23,400,000

Proceeds from issuance warrants

$ 5,700,000

Common stock issued, value

$ 1,873,000

$ 27,000

Subsequent Event [Member] | Cytori Ltd. and Cell Therapy Assets [Member]

Liquidity [Line Items]

Cash proceeds from sale of subsidiary

$ 3,400,000

Subsequent Event [Member] | Cytori Ltd. and Cell Therapy Assets [Member] | Amendment to Loan and Security Agreement [Member]

Liquidity [Line Items]

Payments for principal, interest and fees

$ 1,700,000

Subsequent Event [Member] | Cytori Therapeutics, K.K. and Cell Therapy Assets used in Japan [Member]

Liquidity [Line Items]

Cash proceeds from sale of subsidiary

$ 2,500,000

Subsequent Event [Member] | Cytori Therapeutics, K.K. and Cell Therapy Assets used in Japan [Member] | Amendment to Loan and Security Agreement [Member]

Liquidity [Line Items]

Payments for principal, interest and fees

$ 1,400,000

Nasdaq Stock Market LLC [Member]

Liquidity [Line Items]

Number of consecutive business days no longer able to meet the required closing bid price of common stock

30 days

Minimum bid price of common stock required for Nasdaq listing rule

$ 1

Grace period provided with minimum bid price for Nasdaq listing rule

180 days

Grace date for minimum bid price requirement for Nasdaq listing

Feb. 25, 2019

Common stock minimum bid price required to regain compliance

$ 1

Number of consecutive business days required to regain compliance

10 days

Date to regain compliance after meeting continued listing requirement

Aug. 26, 2019

Additional grace period provided with minimum bid price to regain compliance

180 days

Description of compliance with minimum bid price requirement

We were granted an additional compliance period of 180 calendar days, or until August 26, 2019, in which to regain compliance after meeting the continued listing requirement for market value of publicly held shares and all other initial listing standards for the Nasdaq Capital Market, with the exception of the bid price requirement, and providing notice to Nasdaq staff of our intent to cure the deficiency during this second compliance period, by effecting a reverse stock split, if necessary.

Series C Convertible Preferred Stock [Member]

Liquidity [Line Items]

Number of convertible shares converted into common stock (in shares)

8,400,000

Number of shares callable by warrants (in shares)

7,059,150

Common Stock [Member]

Liquidity [Line Items]

Common stock issued (in shares)

6,723

6,992,736

10,069

Number of shares callable by warrants (in shares)

1

Warrant exercise price (in dollars per share)

$ 0.7986

Common stock issued, value

$ 7,000

Common Stock [Member] | Series C Convertible Preferred Stock [Member]

Liquidity [Line Items]

Number of convertible shares converted into common stock (in shares)

82,645

Common Stock [Member] | B. Riley FBR [Member] | Sales Agreement [Member]

Liquidity [Line Items]

Proceeds from sale of common stock, net

$ 3,800,000

Common stock issued (in shares)

11,000,000

Common Stock [Member] | Lincoln Park [Member]

Liquidity [Line Items]

Proceeds from sale of common stock, net

300,000

Common stock issued (in shares)

0

Common stock issued, value

$ 5,000,000

$ 600,000

Period exercisable from the date of issuance

24 months

Minimum [Member]

Liquidity [Line Items]

Unrestricted cash and cash equivalents

$ 2,000,000

$ 2,000,000

Maximum [Member] | Common Stock [Member] | B. Riley FBR [Member] | Sales Agreement [Member]

Liquidity [Line Items]

Proceeds from sale of common stock, net

$ 6,500,000

Term Loan Obligations (Details)

Term Loan Obligations (Details) - USD ($)	Dec. 31, 2018	Aug. 31, 2018	Jun. 19, 2018	Dec. 29, 2017	May 29, 2015	Mar. 31, 2019	Mar. 31, 2018	May 24, 2018	May 23, 2018	Sep. 20, 2017
Debt Instrument [Line Items]
Number of shares callable by warrants (in shares)								2,300,000	23,400,000
Minimum liquidity covenant						$ 2,000,000
Interest expense						515,000	$ 423,000
Non-cash amortization						$ 200,000	$ 100,000
LIBOR [Member] | Interest Rate Floor [Member]
Debt Instrument [Line Items]
Basis variable rate					1.00%
Term Loan [Member]
Debt Instrument [Line Items]
Origination Date						May 29, 2015
Original Loan Amount					$ 17,700,000
Basis variable rate					7.95%
Maturity date	Jun. 1, 2019					Jun. 1, 2019
Fees amount associated with loan					$ 1,100,000
Number of shares callable by warrants (in shares)					9,444
Warrant exercise price (in dollars per share)					$ 103.50
Date from which warrants are exercisable						Nov. 30, 2015
Warrant expiration date						May 29, 2025
Minimum liquidity covenant	$ 2,000,000				$ 5,000,000					$ 1,500,000
Extended interest-only period	Jun. 1, 2020	Dec. 31, 2018	Dec. 1, 2018			Aug. 1, 2018
Debt instrument, interest-only period	The Fourth Amendment also required that the Company achieve one of the following by January 31, 2019: enter into an asset sale agreement with a minimum unrestricted net cash proceeds to the Company of $4.0 million; enter into a binding agreement for the issuance and sale of its equity securities or unsecured convertible subordinated debt which would result in unrestricted gross cash proceeds of not less than $7.5 million; or enter into a merger agreement pursuant to which the obligations under the Loan and Security Agreement would be paid down to a level satisfactory to Oxford	The Third Amendment extends the interest-only period under the Term Loan to December 31, 2018 and also requires that the Company pay to Oxford, in accordance with its pro rata share of the loans, 75% of all proceeds received (i) from the issuance and sale of unsecured subordinated convertible debt, (ii) in connection with a joint venture, collaboration or other partnering transaction, (iii) in connection with any licenses, (iv) from dividends (other than non-cash dividends from wholly owned subsidiaries) and (v) from the sale of any assets (such requirement, the “Prepayment Requirement”).	The Second Amendment extends the interest-only period under the Term Loan to December 1, 2018 if the Company receives unrestricted gross cash proceeds of at least $15 million from the sale and issuance of the Company’s equity securities on or before August 31, 2018.			The amendment also extended the interest-only period under the Loan and Security Agreement through August 1, 2018, as the Company successfully closed on a financing and received unrestricted net cash proceeds in excess of $5 million on or before December 29, 2017.
Net proceeds excess receives from unrestricted cash				$ 5,000,000
Amendment fee	$ 350,000	$ 50,000	$ 250,000
Percentage of proceeds received		75.00%
Minimum amount to be paid pursuant prepayment requirement		$ 7,000,000
Debt instrument prepayment, description		The Prepayment Requirement does not apply to proceeds from the sale and issuance of the Company’s equity securities, other than convertible debt. The Prepayment Requirement shall apply until an aggregate principle amount of $7.0 million has been paid pursuant to the Prepayment Requirement. However, if less than $7.0 million has been paid pursuant to the Prepayment Requirement on December 31, 2018 then the Company is required to promptly make additional payments until an aggregate principal amount of $7.0 million has been paid.
Debt instrument, covenant compliance						we were in compliance with all of the debt covenants under the Loan and Security Agreement.
Minimum [Member] | Term Loan [Member]
Debt Instrument [Line Items]
Interest rate					8.95%
Net proceeds excess receives from unrestricted cash	4,000,000
Unrestricted gross cash proceeds required to extend interest-only period	$ 7,500,000		$ 15,000,000
Maximum [Member] | Term Loan [Member]
Debt Instrument [Line Items]
Original Loan Amount						$ 3,000,000

Revenue Recognition (Details)

Revenue Recognition (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2019USD ($)ObligationCustomer	Mar. 31, 2018USD ($)CustomerDistributorLicensee
Concentration Risk [Line Items]
Number of performance obligation | Obligation	1
Payment terms with customers	The Company’s contracts do not involve financing elements as payment terms with customers are less than one year.
Development revenue recognized | $	$ 737	$ 917
Customer Concentration Risk [Member] | Revenue Recognized [Member]
Concentration Risk [Line Items]
Number of customers	2	4
Concentration risk percentage	57.00%	66.00%
Customer Concentration Risk [Member] | Accounts Receivable [Member]
Concentration Risk [Line Items]
Number of customers	2	3
Concentration risk percentage	61.00%	75.00%
Number of distributors | Distributor		2
Number of licensee | Licensee		1

Revenue Recognition - Revenue b

Revenue Recognition - Revenue by Product (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Concentration Risk [Line Items]
Revenues	$ 703	$ 731
Consumable [Member]
Concentration Risk [Line Items]
Revenues	663	559
Device [Member]
Concentration Risk [Line Items]
Revenues		94
Other Products [Member]
Concentration Risk [Line Items]
Revenues	40	78
Product [Member]
Concentration Risk [Line Items]
Revenues	$ 703	$ 731

Revenue Recognition - Product R

Revenue Recognition - Product Revenues, Classified by Geographic Location (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Concentration Risk [Line Items]
Revenues	$ 703	$ 731
Product [Member]
Concentration Risk [Line Items]
Revenues	$ 703	$ 731
Concentration risk percentage	100.00%	100.00%
Americas [Member]
Concentration Risk [Line Items]
Revenues	$ 64	$ 45
Concentration risk percentage	9.00%	6.00%
Japan [Member]
Concentration Risk [Line Items]
Revenues	$ 419	$ 578
Concentration risk percentage	60.00%	79.00%
EMEA [Member]
Concentration Risk [Line Items]
Revenues	$ 150	$ 90
Concentration risk percentage	21.00%	12.00%
Asia Pacific [Member]
Concentration Risk [Line Items]
Revenues	$ 70	$ 18
Concentration risk percentage	10.00%	3.00%

Inventories (Details)

Inventories (Details) - USD ($) $ in Thousands	Mar. 31, 2019	Dec. 31, 2018
Inventory Disclosure [Abstract]
Raw materials	$ 663	$ 758
Work in process	662	555
Finished goods	1,678	1,634
Inventory, net	$ 3,003	$ 2,947

Loss per Share (Details)

Loss per Share (Details) - shares shares in Millions	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Dilutive common shares excluded from the calculations of diluted loss per share (in shares)	13.6	2.3
Outstanding Warrants [Member]
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Dilutive common shares excluded from the calculations of diluted loss per share (in shares)	8.9
Options [Member]
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Dilutive common shares excluded from the calculations of diluted loss per share (in shares)	0.1
Preferred Stock and Restricted Stock Awards [Member]
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Dilutive common shares excluded from the calculations of diluted loss per share (in shares)	4.6

Commitments - Additional Inform

Commitments - Additional Information (Details) $ in Millions	3 Months Ended
	Mar. 31, 2019USD ($)
Recorded Unconditional Purchase Obligation [Line Items]
Restricted cash	$ 0.4
Pre-clinical Research Study Obligations [Member]
Recorded Unconditional Purchase Obligation [Line Items]
Contractual obligation, due in next twelve months	1.8
Contractual obligation	$ 2.5
Minimum [Member]
Recorded Unconditional Purchase Obligation [Line Items]
Operating and financing lease, lease term	2 years
Maximum [Member]
Recorded Unconditional Purchase Obligation [Line Items]
Operating and financing lease, lease term	11 years

Commitments - Summary of Lease

Commitments - Summary of Lease Liabilities and Right-of-Use Assets (Details) $ in Thousands	Mar. 31, 2019USD ($)
Assets
Operating	$ 2,153
Financing	215
Total leased assets	2,368
Liabilities
Operating lease liabilities, current	700
Financing lease liabilities, current	130
Operating lease liabilities. noncurrent	1,518
Financing lease liabilities, noncurrent	84
Total lease liabilities	$ 2,432

Commitments - Summary of Leas_2

Commitments - Summary of Lease Costs (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Lease expense:
Operating lease expense	$ 176
Finance lease expense:
Depreciation of right-of-use assets	33
Total lease expense	209
Cash payment information:
Operating cash used for operating leases	176
Financing cash used for financing leases	28	$ 0
Total cash paid for amounts included in the measurement of lease liabilities	$ 204
Weighted-average remaining lease term (years) - operating leases	4 years 10 months 24 days
Weighted-average remaining lease term (years) - finance leases	1 year 9 months 18 days
Weighted-average discount rate - operating leases	7.30%
Weighted-average discount rate - finance leases	5.00%

Commitments - Summary of Future

Commitments - Summary of Future Minimum Annual Lease Payments under Operating and Financing Leases (Details) $ in Thousands	Mar. 31, 2019USD ($)
Financing Leases
Remaining 2019	$ 100
2020	120
2021	7
Total minimum lease payments	227
Less: amount representing interest	(13)
Present value of obligations under leases	214
Less: current portion	(130)
Noncurrent lease obligations	84
Operating Leases
Remaining 2019	527
2020	690
2021	668
2022	281
2023	100
Thereafter	447
Total minimum lease payments	2,713
Less: amount representing interest	(495)
Present value of obligations under leases	2,218
Less: current portion	(700)
Noncurrent lease obligations	$ 1,518

Contingencies (Details)

Contingencies (Details) - Demand for Arbitration [Member] - Bimini Technologies LLC - Sale and Exclusive License/Supply Agreement [Member] - USD ($) $ in Millions	Oct. 29, 2018	Aug. 31, 2018
Recorded Unconditional Purchase Obligation [Line Items]
Potential milestone payment due upon acheivement of gross profit		$ 1
Gross profit from sale of companys puregraft product line		10
Potential milestone payment claimed		$ 1
Proceeds from milestone payment	$ 1

Stockholders' Equity - Preferre

Stockholders' Equity - Preferred Stock (Details) - USD ($)	Jul. 25, 2018	Jul. 17, 2018	Mar. 31, 2019	Mar. 31, 2018	Dec. 31, 2018	May 24, 2018	May 23, 2018
Preferred Stock [Abstract]
Preferred stock, shares authorized (in shares)			5,000,000		5,000,000	5,000,000	5,000,000
Preferred stock, par value (in dollars per share)			$ 0.001		$ 0.001
Preferred stock, shares issued (in shares)			30,233		30,233
Preferred stock, shares outstanding (in shares)			4,540		4,606
Number of shares callable by warrants (in shares)						2,300,000	23,400,000
Common stock issued (in shares)	6,723
Common Stock [Member]
Preferred Stock [Abstract]
Number of shares callable by warrants (in shares)	1
Warrant exercise price (in dollars per share)	$ 0.7986
Common stock issued (in shares)	6,723		6,992,736	10,069
2018 Rights Offering [Member]
Preferred Stock [Abstract]
Number of shares callable by warrants (in shares)		1
Warrant exercise price (in dollars per share)		$ 0.7986
Period exercisable from the date of issuance			30 months
Common stock issued (in shares)	6,723
Gross proceeds from private placement of stock	$ 5,700,000
Redemption price of warrant prior to expiration			$ 0.01
Common stock price per share for warrant redemption			$ 3.63
Number of consecutive trading days for warrant redemption			20 days
Warrants liability fair value			$ 1,500,000		$ 3,100,000
2018 Rights Offering [Member] | Warrant [Member]
Preferred Stock [Abstract]
Number of shares callable by warrants (in shares)		1,050
Warrant exercise price (in dollars per share)		$ 1,000
2018 Rights Offering [Member] | Common Stock [Member]
Preferred Stock [Abstract]
Number of shares callable by warrants (in shares)		1
Series A Convertible Preferred Stock [Member]
Preferred Stock [Abstract]
Preferred stock, shares issued (in shares)			13,500		13,500
Convertible preferred stock			3.60%		3.60%
Preferred stock, shares outstanding (in shares)			0		0
Series B Convertible Preferred Stock [Member]
Preferred Stock [Abstract]
Preferred stock, shares issued (in shares)			10,000		10,000
Preferred stock, shares outstanding (in shares)			1,112		1,112
Series C Convertible Preferred Stock [Member]
Preferred Stock [Abstract]
Preferred stock, shares authorized (in shares)	7,000
Preferred stock, par value (in dollars per share)	$ 0.001
Preferred stock, shares issued (in shares)			6,723		6,723
Preferred stock, shares outstanding (in shares)			3,428		3,494
Number of shares callable by warrants (in shares)	7,059,150
Number of share converted into common stock for each share (in shares)	1,253
Series C Convertible Preferred Stock [Member] | Dividend Paid [Member]
Preferred Stock [Abstract]
Dividends payable					$ 2,500,000
Series C Convertible Preferred Stock [Member] | 2018 Rights Offering [Member]
Preferred Stock [Abstract]
Number of shares callable by warrants (in shares)		20,000
Common Stock and Series B Convertible Preferred Stock [Member] | 2018 Rights Offering [Member]
Preferred Stock [Abstract]
Charge on Non Transferable Subscription Rights		$ 0

Stockholders' Equity - Schedule

Stockholders' Equity - Schedule of Estimated Fair Value Determined Using Option Pricing Model Assumptions (Details)	Mar. 31, 2019$ / shares	Dec. 31, 2018$ / shares
Expected Term [Member]
Class Of Stock [Line Items]
Warrants expected term	1 year 9 months 18 days	2 years 1 month 6 days
Common Stock Market Price [Member]
Class Of Stock [Line Items]
Warrants measurement input	0.26	0.29
Risk-free Interest Rate [Member]
Class Of Stock [Line Items]
Warrants measurement input	0.0238	0.0248
Expected Volatility [Member]
Class Of Stock [Line Items]
Warrants measurement input	1.28	1.25
Resulting Fair Value (Per Warrant) [Member]
Class Of Stock [Line Items]
Warrants measurement input	0.10	0.13

Stockholders' Equity - Summary

Stockholders' Equity - Summary of Change in Level 3 Warrant Liability Value (Details) - Warrant Liability [Member] - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2019	Dec. 31, 2018
Warrant liability
Beginning balance	$ 916	$ 3,148
Change in fair value	(210)	(2,233)
Ending balance	$ 706	$ 916

Stockholders' Equity - Common S

Stockholders' Equity - Common Stock (Details) - USD ($)	Sep. 21, 2018	Jul. 25, 2018	Jun. 01, 2018	Mar. 31, 2019	Dec. 31, 2018	Mar. 31, 2018	Mar. 31, 2019
Common Stock [Abstract]
Proceeds from sale of common stock, net				$ 1,919,000		$ (150,000)
Common stock issued (in shares)		6,723
Common stock issued, value				$ 1,873,000		$ 27,000
Common Stock [Member]
Common Stock [Abstract]
Common stock issued (in shares)		6,723		6,992,736		10,069
Common stock issued, value				$ 7,000
Common Stock [Member] | B. Riley FBR [Member] | Sales Agreement [Member]
Common Stock [Abstract]
Proceeds from sale of common stock, net							$ 3,800,000
Common stock issued (in shares)							11,000,000
Common Stock [Member] | B. Riley FBR [Member] | Sales Agreement [Member] | Maximum [Member]
Common Stock [Abstract]
Proceeds from sale of common stock, net			$ 6,500,000
Common Stock [Member] | B. Riley FBR [Member] | ATM Program [Member] | Sales Agreement [Member]
Common Stock [Abstract]
Proceeds from sale of common stock, net							$ 3,800,000
Common stock issued (in shares)							11,000,000
Common Stock [Member] | B. Riley FBR [Member] | ATM Program [Member] | Sales Agreement [Member] | Maximum [Member]
Common Stock [Abstract]
Proceeds from sale of common stock, net			$ 6,500,000
Common Stock [Member] | Lincoln Park Capital Fund, LLC [Member]
Common Stock [Abstract]
Common stock issued (in shares)				0
Common stock issued, value	$ 5,000,000
Period exercisable from the date of issuance	24 months
Common Stock [Member] | Lincoln Park Capital Fund, LLC [Member] | Securities Purchase Agreement [Member]
Common Stock [Abstract]
Trading Volume of Common Shares	0
Upper Limit on the Price Per Share	$ 0
Common Stock [Member] | Lincoln Park Capital Fund, LLC [Member] | Maximum [Member]
Common Stock [Abstract]
Beneficial ownership percentage of common stock outstanding	4.99%
Common Stock [Member] | Lincoln Park Capital Fund, LLC [Member] | Maximum [Member] | Single Regular Purchase [Member]
Common Stock [Abstract]
Common stock issued (in shares)	250,000
Common Stock [Member] | Lincoln Park Capital Fund, LLC [Member] | Minimum [Member] | Single Regular Purchase [Member]
Common Stock [Abstract]
Common stock issued, value	$ 1,000,000
Common Stock [Member] | Lincoln Park Capital Fund, LLC [Member] | Purchase Agreement [Member]
Common Stock [Abstract]
Proceeds from sale of common stock, net					$ 300,000
Common stock issued (in shares)					600,000
Common Stock [Member] | Lincoln Park Capital Fund, LLC [Member] | Purchase Agreement [Member] | Maximum [Member]
Common Stock [Abstract]
Floor price of per share	$ 0.25

Subsequent Events (Details)

Subsequent Events (Details) - USD ($)	Apr. 29, 2019	Apr. 25, 2019	Apr. 24, 2019	Mar. 31, 2019
Subsequent Event [Line Items]
Impairment of intangible assets				$ 0
Amendment to Loan and Security Agreement [Member] | Subsequent Event [Member]
Subsequent Event [Line Items]
Amendment fee	$ 600,000
Sale of UK Subsidiary and Certain Assets [Member] | Loan and Security Agreement [Member] | Subsequent Event [Member]
Subsequent Event [Line Items]
Cash proceeds from sale of subsidiary			$ 4,000,000
Payments for principal, interest and fees			$ 1,700,000
Sale of UK Subsidiary and Certain Assets [Member] | Amendment to Loan and Security Agreement [Member] | Subsequent Event [Member]
Subsequent Event [Line Items]
Payments for principal, interest and fees	1,700,000
Sale of the Japanese Subsidiary and Certain Assets [Member] | Loan and Security Agreement [Member] | Subsequent Event [Member]
Subsequent Event [Line Items]
Cash proceeds from sale of subsidiary		$ 3,000,000
Payments for principal, interest and fees		$ 1,400,000
Sale of the Japanese Subsidiary and Certain Assets [Member] | Amendment to Loan and Security Agreement [Member] | Subsequent Event [Member]
Subsequent Event [Line Items]
Payments for principal, interest and fees	$ 1,400,000